Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Management call scheduled for
Citius Chairman and CEO,
Conference Call Details:
Date: |
|
Time: |
8:30 a.m. Eastern Time |
Dial In: |
1-412-317-5413 (international) |
Webcast: |
Register for the webcast here. A replay will be available on the Citius website (www.citiuspharma.com) for 90 days following the event. |
About
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates: Mino-Lok® and LYMPHIR™. In
Investor Contact:
ir@citiuspharma.com
908-967-6677 x113
Media Contact:
STiR-communications
Greg@STiR-communications.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-host-investor-call-to-discuss-topline-results-of-phase-3-trial-of-mino-lok-antibiotic-lock-solution-302157598.html
SOURCE